Drug research
Explore 1,813 drugs with active development programs.
Move from a drug to its verified developers, clinical trials, indications and FDA decisions.
- Drug programs
- 1,813
- Index
- A–Z
- Evidence
- Trials · FDA · developers
Featured directory
Most-developed drug programs
Browse the 200 programs with the broadest active development footprint below, or choose an initial for all 1,813.
Browse A–Z
- ofatumumab6
- imatinib5
- risperidone5
- buprenorphine4
- ensifentrine4
- levothyroxine4
- lotilaner4
- memantine4
- pegcetacoplan4
- pitolisant4
- sarilumab4
- zolpidem4
- aleniglipron3
- apixaban3
- avlayah3
- belatacept3
- botulinum toxin type A3
- canakinumab3
- carboprost3
- casimersen3
- cipaglucosidase alfa3
- dexmedetomidine3
- elelyso3
- elraglusib3
- eteplirsen3
- fingolimod3
- gefitinib3
- granisetron3
- icosapent ethyl3
- ifetroban3
- lumateperone3
- lutetium lu-177 vipivotide tetraxetan3
- lymphir3
- midostaurin3
- navenibart3
- ngenla3
- nintedanib3
- palazestrant3
- pantoprazole3
- pemvidutide3
- piflufolastat f-183
- pimavanserin3
- rabeprazole3
- remibrutinib3
- sodium3
- sodium nitroprusside3
- sparsentan3
- tirzepatide3
- tovecimig3
- upadacitinib3
- xiaflex3
- zelenectide pevedotin3
- zuranolone3
- abiraterone2
- abrocitinib2
- acalabrutinib2
- adalimumab2
- adxs-psa2
- aficamten2
- ag102
- aglatimagene besadenovec2
- albuterol sulfate; budesonide2
- alpelisib2
- amifampridine2
- amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine2
- amzeeq2
- anti-fcrn monoclonal antibody imvt-14022
- apomorphine2
- aripiprazole lauroxil2
- atazanavir2
- atorvastatin2
- atrasentan2
- auryxia2
- avapritinib2
- avexitide2
- azetukalner2
- baricitinib2
- belrestotug2
- bexobrutideg2
- bezuclastinib2
- bicalutamide2
- bivalirudin2
- bivamelagon2
- budesonide; formoterol2
- busulfan2
- cabazitaxel2
- cabozantinib s-malate2
- carbidopa; levodopa2
- ceritinib2
- cetirizine2
- chs-1142
- cinacalcet2
- cyclophosphamide2
- dabogratinib2
- daclatasvir2
- dacomitinib2
- dasatinib2
- deferasirox2
- deutetrabenazine2
- deutivacaftor; tezacaftor; vanzacaftor2
- dexamethasone2
- dicyclomine2
- divalproex2
- docetaxel2
- dronedarone2
- dulaglutide2
- elexacaftor2
- eltrombopag olamine2
- emavusertib2
- emrosi2
- enasidenib2
- envudeucitinib2
- ephedrine2
- epidiolex2
- eribulin2
- erythromycin lactobionate2
- esomeprazole magnesium2
- etigilimab2
- exagamglogene autotemcel2
- fedratinib2
- fesoterodine2
- fexofenadine2
- ficerafusp alfa2
- fluphenazine2
- fluvoxamine2
- formoterol2
- gavreto2
- glecaprevir2
- glycopyrrolate2
- gocovri2
- histrelin2
- ibandronate2
- iluvien2
- imetelstat2
- inclisiran2
- indacaterol2
- infigratinib2
- insulin glargine2
- insulin, regular, human2
- isoproterenol2
- ixekizumab2
- ketoprofen2
- keveyis2
- larotrectinib2
- larsucosterol2
- levetiracetam2
- lonigutamab2
- lorlatinib2
- lurasidone2
- lurbinectedin2
- luveltamab tazevibulin2
- maralixibat2
- mecbotamab vedotin2
- methylene blue2
- methylphenidate2
- micvotabart pelidotin2
- migalastat2
- miglustat2
- montelukast2
- naltrexone hydrochloride; oxycodone2
- namzaric2
- navicixizumab2
- nebivolol2
- nelarabine2
- nexobrid2
- nilotinib2
- nogapendekin alfa inbakicept2
- nuzefatide pevedotin2
- obexelimab2
- ojemda2
- olpruva2
- omaveloxolone2
- omega-3-carboxylic acids2
- omeprazole magnesium2
- orladeyo2
- ozuriftamab vedotin2
- palonosetron2
- paltusotine2
- paroxetine2
- paxlovid2
- peginterferon beta-1a2
- perampanel2
- petosemtamab2
- pirtobrutinib2
- plozasiran2
- poziotinib2
- praliciguat2
- procainamide2
- prochlorperazine edisylate2
- ralinepag2
- ramucirumab2
- recorlev2
- resmetirom2
- revumenib2
- rolvedon2
- rosnilimab2
- rylaze2
- sapanisertib2
- selpercatinib2
- selumetinib2
From drug map to evidence case
Define what a drug program must prove
Choose the developer, phase, trial, indication, and FDA evidence that should count in your drug thesis.